Seven Years of Clinical Experience Outcome Review on Radium 223 Therapy In Bone Metastatic Castrate-resistant Prostate Cancer (mCRPC)

被引：0
|
作者：
Cantinho-Lopes, M. [1 ]
Pena, H. [1 ]
Filipe, P. [2 ]
Mansinho, A. [2 ]
Fernandes, I. [2 ]
Costa, L. [2 ]
机构：
[1] Fac Med Lisbon, Inst Med Nucl, Lisbon, Portugal
[2] CHULN, S Oncol, Lisbon, Portugal
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2022年 / 49卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EPS-225
引用
收藏
页码：S400 / S400
页数：1
相关论文
共 50 条
  • [41] Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Mar, Nataliya
    Dwabe, Sami
    Baranda, Marlon N.
    Zarrabi, Kevin K.
    Eturi, Aditya
    Gulati, Shuchi
    Parikh, Mamta
    Seyedin, Steven N.
    Kalebasty, Arash Rezazadeh
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 217 - 223
  • [42] EARLY EXPERIENCE OF RADIUM-223 TREATMENT FOR METASTATIC CASTRATE RESISTANT PROSTATE CANCER: A PRELIMINARY REPORT
    Bienz, Marc
    Alom, Modar
    Mouravieva, Vladimira
    Zehel, Debby
    Pieczonka, Christopher
    Albala, David
    Williams, Howard
    Mouraviev, Vladimir
    Mariados, Neil
    JOURNAL OF UROLOGY, 2014, 191 (04): : E806 - E806
  • [43] Initial experience of radium-223 treatment for metastatic castrate resistant prostate cancer in community setting
    Pieczonka, Christopher Michael
    Bienz, Marc Nicolas
    Mouravieva, Vladimira
    Albala, David
    Mouravlev, Vladimir
    Marlados, Nell
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer
    Nemtsova, E. R.
    Pankratov, A. A.
    Morozova, N. B.
    Tischenko, V. K.
    Petriev, V. M.
    Krylov, V. V.
    Shegay, P. V.
    Ivanov, S. A.
    Kaprin, A. D.
    BIOLOGY BULLETIN, 2022, 49 (12) : 2285 - 2297
  • [45] AUSTRALIAN EXPERIENCE WITH CABAZITAXEL IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER (mCRPC)
    Ng, S.
    Gurney, H.
    Parente, P.
    Bahre, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 63 - 63
  • [46] Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer
    Parikh, S.
    Murray, L.
    Kenning, L.
    Bottomley, D.
    Din, O.
    Dixit, S.
    Ferguson, C.
    Handforth, C.
    Joseph, L.
    Mokhtar, D.
    White, L.
    Wright, G.
    Henry, A. M.
    CLINICAL ONCOLOGY, 2018, 30 (09) : 548 - 555
  • [47] Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer
    E. R. Nemtsova
    A. A. Pankratov
    N. B. Morozova
    V. K. Tischenko
    V. M. Petriev
    V. V. Krylov
    P. V. Shegay
    S. A. Ivanov
    A. D. Kaprin
    Biology Bulletin, 2022, 49 : 2285 - 2297
  • [48] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
    Thomson, Alastair
    Pollard, Adam
    Mark, Frances May
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [49] The Sequencing Conundrum in Metastatic Castrate-resistant Prostate Cancer (mCRPC): the Rosemere Cancer Centre Experience to Unlocking the Optimal Sequence
    Pan, S.
    Kumar, V.
    Charnley, N.
    Parikh, O.
    Birtle, A.
    CLINICAL ONCOLOGY, 2016, 28 (05) : E14 - E14
  • [50] Olaparib in metastatic castrate-resistant prostate cancer
    不详
    BJU INTERNATIONAL, 2020, 126 (02) : 235 - 235
12345